MDS Pharma Services Launches Next Generation Phase I Study Management System
07 Juli 2008 - 3:00PM
PR Newswire (US)
Proprietary ClinQuick(R) system builds on a 15-year track record of
technical leadership in early clinical research KING OF PRUSSIA,
PA, July 7 /PRNewswire-FirstCall/ -- MDS Pharma Services, a leading
provider of innovative drug discovery and development solutions,
has launched the next generation of its proprietary ClinQuick(R)
electronic system for Phase I study set-up, data capture, project
tracking and personnel credential management. Aimed at improving
client service, the new version of the ClinQuick(R) system extends
a 15-year legacy of technical leadership in early clinical
research. System enhancements include a more user-friendly
interface, improved menu navigation and a more robust data
platform. This new platform will enable faster and more flexible
reporting and will ultimately allow clients to access their data
via the internet. "Since its implementation in 1993, ClinQuick(R)
has been used successfully in more than 3,000 Phase I studies
involving nearly 100,000 participants," said MDS Pharma Services
President David Spaight. "Our investment to enhance the
ClinQuick(R) system builds on that legacy of success and will allow
us to meet growing client demand for early clinical research
services while maintaining our leadership position in Phase I. This
next-generation ClinQuick(R) system will further improve our
ability to deliver high quality Phase I services on time." About
ClinQuick(R) Designed and built by MDS Pharma Services for use in
its Phase I clinical research centers, the fully integrated
ClinQuick(R) system facilitates rapid data cleansing and client
monitoring for seamless operation of both single and multi-site
studies. ClinQuick(R) accelerates timelines, enables accurate
direct data acquisition, and reduces costs by a third compared to
traditional paper case report forms (CRFs) - the forms used by
clients to collect and document data from each participating
clinical research site. The system is fully CFR Part 11 compliant
and can be used for study management and electronic data capture
(EDC), either alone or in conjunction with a client-provided EDC
system or paper CRFs. MDS Pharma Services offers one of the world's
largest capacities for conducting early-phase clinical studies,
with some 1,100 beds in five state-of-the-art clinical research
facilities in North America and Europe. About MDS Pharma Services
MDS Pharma Services is committed to delivering quality service on
time. We offer a full spectrum of resources to meet the drug
discovery and development needs of the pharmaceutical and
biotechnology industries. With numerous facilities strategically
located around the world, we apply advanced scientific and
technological expertise throughout the drug discovery and
development process - from lead optimization, pre-IND research,
early clinical research (bioequivalence, phases I-IIa) and
bioanalysis through to global clinical development (phases IIb-IV),
central lab and centralized cardiac services. For more information,
visit our website at http://www.mdsps.com/. MDS Pharma Services is
a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ), a global life
sciences company that provides market-leading products and services
that our customers need for the development of drugs and diagnosis
and treatment of disease. We are a leading global provider of
pharmaceutical contract research, medical isotopes for molecular
imaging, radiotherapeutics, and analytical instruments. MDS has
more than 5,500 highly skilled people in 29 countries. Find out
more at http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24
hours a day. DATASOURCE: MDS Pharma Services CONTACT: For
Investors, Kim Lee, (416) 675-6777 ext. 34721, ; For Media,
Charlene McGrady, (610) 239-7900 ext. 231,
Copyright